EVE Health Group (ASX:EVE) Completes Nextract Acquisition
EVE Health Group (ASX:EVE) completes acquisition of Nextract, bolstering its position in the healthcare market.
Category: Healthcare
AnteoTech Ltd (ASX:ADO) Reports 130% Sales Growth in Life Sciences Unit
AnteoTech Ltd (ASX:ADO) reports a 130% sales increase in its Life Sciences unit and secures a significant order from the Serum Institute of India.
dorsaVi Ltd (ASX:DVL) Secures Exclusive Worldwide Licence for Advanced RRAM Technology
dorsaVi Ltd (ASX:DVL) secures an exclusive worldwide licence for advanced RRAM technology, enhancing its wearable sensors and expanding market opportunities.
Bioxyne Limited (ASX:BXN) Upgrades FY2025 Revenue Guidance
Bioxyne Limited (ASX:BXN) upgrades its FY2025 revenue guidance to $28m, driven by significant growth in Australian operations and European expansion.
HITIQ Limited (ASX:HIQ) Announces Exclusive Global Agreement with Shock Doctor
HITIQ Limited (ASX:HIQ) forms an exclusive global partnership with Shock Doctor to enhance concussion management through the PROTEQT instrumented mouthguard.
Noxopharm Limited (ASX:NOX) Announces Positive Sofra™ Data from BioRay Collaboration
Noxopharm Limited (ASX:NOX) announces positive Sofra™ data from BioRay collaboration, validating its anti-inflammatory potential.
PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
4DMedical Limited (ASX:4DX) Partners with Olympus to Launch SeleCT™ Screening Campaign
4DMedical Limited (ASX:4DX) partners with Olympus to deploy AI-powered SeleCT™ Screening, enhancing COPD diagnosis and treatment.
Radiopharm Theranostics (ASX:RAD) Receives FDA Fast Track for RAD101
Radiopharm Theranostics (ASX:RAD) secures FDA Fast Track for RAD101, advancing its Phase 2 trial in brain metastases imaging.
Syntara Limited (ASX:SNT) Receives FDA Fast Track Designation for SNT-5505
Syntara Limited (ASX:SNT) secures FDA Fast Track for its myelofibrosis treatment SNT-5505, accelerating its development towards becoming a new standard of care.